Pembrolizumab in Treating Patients With Malignant Mesothelioma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT02399371
Phase
PHASE2
Status
Completed

Conditions

  • Biphasic Mesothelioma
  • Epithelioid Mesothelioma
  • Peritoneal Malignant Mesothelioma
  • Pleural Biphasic Mesothelioma
  • Pleural Epithelioid Mesothelioma
  • Pleural Malignant Mesothelioma
  • Pleural Sarcomatoid Mesothelioma
  • Recurrent Peritoneal Malignant Mesothelioma
  • Recurrent Pleural Malignant Mesothelioma
  • Sarcomatoid Mesothelioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — BIOLOGICAL
    Given IV
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Pharmacogenomic Study — OTHER
    Correlative studies

Study Details

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.

Key Dates

Start date
Mar 31, 2015
Status verified
Apr 2026
Primary completion
Aug 13, 2024
Completion
Mar 20, 2026

Study Design

Enrollment
65 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (pembrolizumab)
    Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.

Primary Outcome Measure

Ability of PD-L1 to Predict Response [ Time Frame: Up to 1 year ]

Locations (1)

FacilityCityStateZIP
University of ChicagoChicagoIllinois60637

Related coverage on Hipa.ai

Find similar trials in Chicago, IL

By research site
University of Chicago· Chicago, IL

Related Studies